8月20日，葛兰素史克盘中上涨3.01%，报52.685美元/股，成交额1.42亿美元。
消息面上，制药板块当日集体走强，同业默沙东大涨13.16%、礼来涨4.82%、辉瑞涨3.89%，板块资金流入明显。公司层面，近日利好密集释放：8月18日，中外制药与GSK签署抗登革热病毒抗体AID351独家许可协议，GSK获得该药物全球独家开发、生产和商业化权利；同日，核心产品NUCALA获加拿大药品管理局积极报销推荐，适应症拓展至成人慢性阻塞性肺疾病。此外，公司此前二季度财报绩后曾大涨超7%，销售额84亿英镑同比增长5%，管线推进节奏良好，市场情绪持续偏暖。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.